Chimerix Inc

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals to address unmet medical needs in the United States. The company’s lead compounds include brincidofovir (CMX001), an oral nucleotide analog that is in Phase III clinical trial for the prevention of cytomegalovirus (CMV) in adult hematopoietic cell transplant recipients, as well as to treat…More adenovirus infection; and CMX157, a nucleotide analog for the treatment of HIV and hepatitis B virus infections. Its preclinical testing product includes CMX669 for the treatment of BK virus and CMV.